» Articles » PMID: 32252653

Causative Factors of Liver Fibrosis in HIV-infected Patients. A Single Center Study

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2020 Apr 8
PMID 32252653
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Liver disease is a leading cause of morbidity and mortality among Human Immunodeficiency virus (HIV) infected patients; however no consensus exists on HIV-related risk factors for it. The aim of this study was to identify risk factors for liver fibrosis/cirrhosis in a cohort of Greek HIV-infected patients.

Methods: Patients attending the HIV outpatient clinic of Pathophysiology Department at «Laiko» General Hospital in Athens, Greece, between December 2014 and December 2017 were eligible for inclusion. Inclusion criteria were confirmed HIV infection and age > 18 years. Exclusion criteria were Body-Mass index (BMI) > 40, liver metastases of malignant diseases and concurrent or previous chemotherapy. Liver stiffness (LS) was measured using Vibration Controlled Transient Elastography (TE) and laboratory tests were acquired in all patients. Patients were classified in 2 groups: those with mild or no fibrosis (equivalent to Metavir score F0-F2) and those with significant fibrosis (equivalent to Metavir score F3-F4).

Results: A total of 187 consecutive patients were included in this study. Median TE value was 5.1 kilopascals (KPa) (range 2.8-26.3), with 92.5% (173/187) of the patients having no/mild fibrosis and 7.4% (14/187) significant fibrosis. On multivariate logistic regression analysis older patient's age, abnormal serum aspartate aminotransferase (AST) value, Hepatitis C virus (HCV) infection, alcohol abuse, CD4/CD8 ratio and an increased number of liver related events (LREs) were significantly correlated with liver fibrosis/cirrhosis.

Conclusions: In our cohort of HIV-infected individuals HCV/HIV co-infection, older age, alcohol abuse and CD4/CD8 ratio seem to correlate with fibrogenesis in the liver.

Citing Articles

Hepatitis B and C Virus Co-Infection and Their Association With Liver Disease in Persons With HIV in Nigeria.

Odeghe E, Oyeleke G, Odofin M, Duguru M, Davwar P, Nyam D J Int Assoc Provid AIDS Care. 2024; 23:23259582241292511.

PMID: 39469965 PMC: 11528674. DOI: 10.1177/23259582241292511.


Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy.

Srisopa S, Pipatsatitpong D, Akekawatchai C Biomed Rep. 2024; 21(4):146.

PMID: 39170754 PMC: 11337153. DOI: 10.3892/br.2024.1834.


Predictors of severe hepatotoxicity among retroviral infected adults on HAART regimen in Ilubabor Zone, Southwest Ethiopia.

Darge T, Babusha A, Chilo D, Dukessa A, Teferi S Sci Rep. 2024; 14(1):8473.

PMID: 38605149 PMC: 11009247. DOI: 10.1038/s41598-024-57900-7.


Liver Transplantation in People Living with HIV: Still an Experimental Procedure or Standard of Care?.

Lynch E, Russo F Life (Basel). 2023; 13(10).

PMID: 37895356 PMC: 10608432. DOI: 10.3390/life13101975.


CD4/CD8 Ratio Recovered as a Predictor of Decreased Liver Damage in Adults Infected With HIV: 16-Year Observational Cohort Study.

Liang B, Sun R, Liao Y, Nong A, He J, Qin F JMIR Public Health Surveill. 2023; 10():e45818.

PMID: 37846087 PMC: 10806443. DOI: 10.2196/45818.


References
1.
Piccinino F, Sagnelli E, Pasquale G, Giusti G . Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2(2):165-73. DOI: 10.1016/s0168-8278(86)80075-7. View

2.
Han S, Kim S, Kim C, Jeong S, Park J, Choi J . Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. PLoS One. 2013; 8(1):e52720. PMC: 3536776. DOI: 10.1371/journal.pone.0052720. View

3.
Cross T, Calvaruso V, Maimone S, Carey I, Chang T, Pleguezuelo M . Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2009; 17(8):546-54. DOI: 10.1111/j.1365-2893.2009.01210.x. View

4.
Jellinger P, Handelsman Y, Rosenblit P, Bloomgarden Z, Fonseca V, Garber A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017; 23(Suppl 2):1-87. DOI: 10.4158/EP171764.APPGL. View

5.
Cassinotto C, Boursier J, de Ledinghen V, Lebigot J, Lapuyade B, Cales P . Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2015; 63(6):1817-27. DOI: 10.1002/hep.28394. View